A groundbreaking treatment, retatrutide, is creating considerable anticipation within the Australian weight loss community. Designed by Lilly , this dual GIP and GLP-1 receptor appears to deliver more impressive outcomes than existing therapies. Initial clinical research have shown remarkable dec